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The clinical applications of
18F-fluoro-2-deoxyglucose (
18FDG) positron emission tomography (PET) in oncology are becoming
established. While simple static scanning techniques are used for the majority of routine clinical examinations, increasing use of PET in
clinical trials to monitor treatment response with
18FDG and novel tracers reflecting different pharmacodynamic end points, often
necessitates a more complex and quantitative analysis of radiopharmaceutical kinetics. A wide range of PET analysis techniques exist,
ranging from simple visual analysis and semiquantitative methods to full dynamic studies with kinetic analysis. These methods are
discussed, focusing particularly on the available methodologies that can be utilised in clinical trials.
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18F-fluoro-2-deoxyglucose (
18FDG) positron emission tomography
(PET) is an important tool in oncology, at the forefront of
functional and molecular imaging techniques. Its use has
progressed from staging purposes to the assessment of response
to treatment (Figure 1). The information derived from
18FDG PET
scans is more frequently becoming the basis for decisions on
subsequent management, such as the cessation or switching of
chemotherapy regimes and the addition or modification of
radiotherapy. It is also used clinically to establish the diagnosis
of relapse following treatment.
There is a wealth of literature reporting on the role of
18FDG
PET in malignancy, showing a wide range of associated
sensitivities and specificities; frequently showing greater accuracy
than other forms of conventional imaging in a number of tumour
types. One of the explanations for the range of reported results
may be due to the variability of scanning protocols and analytic
techniques used. The analytic techniques range from simple visual
qualitative assessment and semiquantitative methods, for example,
standardised uptake value (SUV) measurement, to full kinetic
analysis with compartmental modelling, for example, nonlinear
regression analysis (NLR). A variety of analytical methods have
been proposed that need to be validated for different tumour types
and for assessing therapeutic response. While simple qualitative
techniques are sufficient for many routine clinical examinations,
an increase in the use of PET with
18FDG, and also novel tracers
reflecting different pharmacodynamic end points in clinical trials,
often necessitates a more complex and quantitative approach.
PHYSIOLOGY OF
18FDG UPTAKE
Accelerated glucose metabolism is the basis for the use of
18FDG
PET in detecting cancer.
18F-fluoro-2-deoxyglucose is transported
into glucose-consuming cells with the aid of transporters such as
GLUT-1, where it is phosphorylated by hexokinases. Overexpres-
sion of glucose transporters and hexokinases has been reported
in many cancer cells, leading to their increased accumulation of
phosphorylated
18FDG (Smith, 2001). Unless dephosphorylation
occurs by glucose-6-phosphatase,
18FDG-6-PO4 remains essentially
trapped in the cell. After initial accumulation, there is often rapid
dephosphorylation and clearing of FDG-6-PO4 in tissues and
organs with high glucose-6-phosphatase activity (Caraco et al,
2000). Malignant cells mostly show low levels of glucose-6-
phosphatase compared with many normal tissues and benign
pathological processes such as inflammation, leading to different
kinetics of
18FDG accumulation between benign and malignant
processes (Yamada et al, 1995; Lodge et al, 1999; Nakamoto et al,
2000).
FACTORS AFFECTING
18F-FDG UPTAKE AND SCAN
INTERPRETATION
Pathological processes other than malignancy can be responsible
for some degree of initial increase in uptake, predominantly
infective, inflammatory and granulomatous disorders (e.g., tuber-
culosis, aspergillosis, sarcoidosis, amyloidosis and postradiother-
apy reactions) (Cook et al, 1996). This is thought to be due to
uptake in the increased number of activated white cells involved in
these processes and can produce a false-positive scan (Kaim et al,
2002). Uptake also depends on various other factors, such as
body habitus, insulin levels and blood glucose (Huang, 2000).
18F-fluoro-2-deoxyglucose accumulation is influenced by tumour
blood flow but other factors such as glucose transport and
hexokinase activity are frequently rate-limiting steps, although a
single factor probably does not account for
18FDG uptake in all
tumours (Smith, 2001).
The performance characteristics of the PET scanner, scan timing
and duration, measurement of injected activity and a number of
other technical factors can all affect precision and accuracy of
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scanner is usually between 5 and 8mm in the reconstructed
image. Uptake in structures less than two to three times this size
can be underestimated as a result of the partial volume effect. For
example, a sphere with a diameter equivalent to 1.5 times the
spatial resolution will have a maximum measured activity
concentration of about 60% of the true activity concentration
and a mean of about 30% (Geworski et al, 2000). Heterogeneity of
uptake in tumours (e.g., when areas of viable and necrotic tumour
exist) can cause similar problems in accurate quantitation of viable
tumour activity. Higher activity in surrounding tissues to the
region of interest (ROI) can contribute to activity within the ROI
by the spillover effect and this may also affect noninvasive
measurements of arterial activity concentration (e.g., aorta or left
ventricle) when used as a noninvasive method of obtaining an
arterial input function (IF) for kinetic analytical methods
(Cook et al, 1999).
The recent introduction of hybrid PET/CT (computed tomo-
graphy) scanners allows combined modality acquisitions in a
single sitting. The anatomical detail provided by CT allows better
localisation of sites of physiologic activity and pathology identified
by PET, thereby improving image interpretation and also
providing rapid, low-noise transmission CT data for attenuation
correction of PET emission data, essential for quantitative
measurements.
A range of software platforms and packages are available for
PET data processing and analysis offering different levels of
flexibility and complexity to the user (Ratib, 2004). The increasing
use of PET/CT has also led to the demand for better software
platforms for the reconstruction and optimal display and analysis
of both sets of images in a user-friendly format.
TIME COURSE OF
18FDG UPTAKE AND THE
OPTIMUM TIME OF IMAGE ACQUISITION
Studies have investigated uptake over time in malignant cells,
some tumour-specific, for example, lung cancer and sarcomas,
comparing uptake with that in benign and inflammatory lesions
(Lodge et al, 1999; Matthies et al, 2002). The maximum uptake in
benign tissues occurs earlier at approximately 30min, with peak
uptake in inflammatory tissues occurring at about 60min (Yamada
et al, 1995). There is a wider spectrum for malignant tissues, with
peak uptake occurring later, sometimes up to 4h (Lodge et al,
1999). More consistent and reliable measurements are likely to be
possible when tumour tracer concentration has reached a plateau,
as small differences in the timing of scans after injection are
less likely to affect measured parameters of uptake. This creates
difficulties in establishing an optimum scanning time as the half-
life of the radioisotope must also be considered (110min for
18F).
The EORTC and NCI guidelines both recommend an optimum
scanning time of 50–70min (Young et al, 1999; Shankar et al, 2006),
and this is usually the time taken for clinical scans as a best compromise
between tumour to background contrast and decay of tracer.
METHODS OF IMAGE ACQUISITION
Static emission scans are made during a period when the activity
distribution is assumed to be fairly stable with a counting time
long enough to obtain a good quality image, usually between 3 and
5min on modern scanners with three-dimensional acquisition.
Several bed positions (each covering between 10 and 20cm) are
required to image the whole body. Dynamic scans are carried out
by acquiring a continuous series of image frames that can be of
various lengths. Early frames are usually shorter to allow kinetic
measurements when tracer concentrations are changing rapidly,
with longer frames towards the end of a study. Dynamic emission
scans are usually acquired from 0 to 60min for
18FDG. One bed
position only is used, limiting the area visualised. Region of
interests can be placed and a tissue time–activity curve calculated.
Some form of vascular IF is required for analysis for some of the
more complex kinetic analytical methods. This can be derived
from direct arterial sampling or indirectly by measuring activity
over an arterial ROI.
IMAGE ANALYSIS
Qualitative analysis
Qualitative interpretation involves simple visual analysis of a static
scan by the reporter. Interpretation is based on contrast in uptake
between a lesion and surrounding tissues and is dependent on
uptake time, blood glucose and insulin levels, and also the nature
of the surrounding tissues. In small tumours with low uptake
close to normal tissue with high uptake, lesions may become
inconspicuous. Following therapy, normal tissue may also undergo
physiological changes. For these reasons, visual subjective analysis
has poor reproducibility and although it may be suitable for some
routine clinical work, it is often insufficient for clinical trials where
objective parameters of response are usually required and
recommended (Weber, 2005; Shankar et al, 2006).
Semiquantitative analysis
Tumour-to-background normal tissue ratio (T/N) requires a static
image and is potentially subject to some of the weaknesses of
visual analysis. Even when there has been no change in uptake in
malignant tissues, a change in the normal tissue uptake post
therapy can lead to a change in the T/N ratio. It is generally
regarded as a less reliable index than the SUV. The SUV is the ratio
between the tumour concentration of
18FDG and its concentration
in the entire body if the tracer is uniformly distributed throughout.
It has also been referred to as the differential uptake ratio or the
differential absorption ratio. Its measurement requires a static,
attenuation-corrected scan, accurate calibration and body weight
for normalisation. Normalisation to body surface area or lean body
mass may be advantageous. There is also debate about whether it
should be corrected for blood glucose, as an improvement in
precision has been suggested, but there is no consensus (Thie,
2004). Standardised uptake values are dependent on the uptake
time but are most commonly measured at 60min after injection.
Figure 1 A liver metastasis from a gastric GIST before (A) and 1 week
after (B) commencing imatinib therapy. FDG PET/CT scans, unenhanced
CT (left), fused FDG PET and CT (right). Although there has been no
morphological change in the metastasis, the abnormal baseline metabolic
activity (colour scale) has rapidly resolved indicating sensitivity to the drug.
The SUV fell from 5.0 to 1.8.
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tissue vary among different malignancies, often lying between 2
and 3, but this may be variable for different types of tumour. Best
documented is the cutoff of 2.5 used in pulmonary lesions (Lowe
et al, 1998). There is frequently an area of overlap that can limit its
use in an individual patient, some tumours not being
18FDG-avid
and some benign processes showing high
18FDG uptake. It is a
more reliable index to monitor change within the same patient and
is reasonably precise, with less than 10% variation reported in
pretreatment scans providing attention is paid in performing
consecutive scans in exactly the same way (Minn et al, 1995).
Standardised uptake values are computationally simple and
make some of the same assumptions as qualitative analysis. The
measured




nonphosphorylated extracellular (intravascular and interstitial)
18FDG. Of these components, the first is most directly related to the
metabolic activity of tumour cells. Static scans cannot differentiate
between the different components and therefore do not necessarily
correlate with glucose metabolic rates. They do not take into
account the physiological changes affecting the availability of
18FDG. This may be of particular importance in assessing response
to therapy, when there may be changes in the distribution of
18FDG
throughout the body and also in the uptake by the lesion.
Dual-point scanning often uses semiquantitative indices such as
SUV but exploits the different kinetics between benign and
malignant tissue by comparing activity at two time points, usually
at 60 and 120min, with a number of studies reporting better tissue
characterisation when benign and malignant lesions exist (Yamada
et al, 1995; Nakamoto et al, 2000; Matthies et al, 2002; Ratib, 2004).
Quantitative analysis
Simplified kinetic analysis Simplified kinetic analysis is a generic
term for methods that attempt to estimate tumour glucose
metabolic rate without the need for full dynamic studies or
arterial blood measurements but at the same time overcoming
some of the limitations of SUVs. They usually rely on a single time
point (SKA-S) static image and a single timed blood sample
(Hunter et al, 1996), but, more recently, multiple time point
(SKA-M) methods have been proposed (Sundaram et al, 2004)
with reports of lower variability and bias compared with SKA-S.
Kinetic analysis Full quantitative analysis uses kinetic modelling
approaches to derive the metabolic rate for glucose (MRglu)o r
18FDG (MRFDG). Dynamic studies follow metabolic activity over a
longer period of time, using a more complex model of the
underlying physiology and seeking to remove more of the effects
of confounding factors. They are less dependent on the time of
measurement. The kinetic models are based on the concept of
several compartments that contain
18FDG, linked by kinetic
processes that provide a mechanism of exchange of
18FDG
(Willemsen and Van den Hoff, 2002). Rate constants (k) describe
the rate of movement of
18FDG between compartments. These are
assumed to represent specific physiological processes such as
blood flow, glucose metabolism and enzyme activity. The transport
of
18FDG across the capillary/cellular membrane is accounted for
by the rate constants K1 and k2 (forward and reverse transport).
The phosphorylation of
18FDG to
18FDG-6-PO4 is represented by k3
and sometimes a small dephosphorylation rate constant, k4, for the
dephosphorylation of
18FDG. Ki (K1k3/(k2þk3)) is the net influx
rate constant for
18FDG. Certain assumptions have to be made
related to the biological system and
18FDG and to the specific
experimental procedure employed to make the measurements. The
processes of the biological system influencing the kinetic
behaviour of
18FDG are assumed to be in steady state, although
the
18FDG concentration itself does not have to be in a steady state.
The data in dynamic studies are obtained from a series of image
frames as described earlier. An IF is measured from either arterial
or arterialised venous blood sampling. More recently, noninvasive
measurement of arterial activity in the aorta or left ventricle
dynamic image data has been validated (Hoekstra et al, 2002).
Nonlinear regression analysis uses an algorithm to derive values
for the rate constants and also a blood volume term. It uses a two-
tissue compartmental model with an arterial plasma IF and tissue
time–activity data (tissue TAC) over 0–60min to measure Ki.I t
provides one of the most accurate estimates of tumour glucose use
(Dimitrakopoulou-Strauss et al, 2002). In clinical practice, low
count statistics and artefacts attributable to patient movement can
affect its accuracy.
Patlak graphical analysis requires fewer image frames than NLR
but still requires a blood IF (Patlak et al, 1983). A tissue TAC is
provided from the dynamic image data and the net metabolic
clearance of
18FDG can then be calculated. The rate of uptake from
the plasma is given by the slope of the linear portion of the plot. Ki
can therefore be derived and the tissue metabolic rate of glucose is
calculated. This method assumes that k4¼0, that is, irreversible
trapping of
18FDG-6-PO4. Patlak analysis has been shown to
approach the accuracy of NLR but is computationally simpler and
considered less susceptible to image noise (Weber, 2005).
CLINICAL APPLICATIONS
Tissue differentiation and tumour grading
The initial role of
18FDG PET was in the differentiation between
benign and malignant lesions, especially in indeterminate solitary
pulmonary nodules (Lowe et al, 1998) with further exploration into
grading and prognosis assessment of various tumours (Dimitra-
kopoulou-Strauss et al, 2001; Shimoda et al, 2007). Standardised
uptake values have been shown to be reliable in differentiating
between benign and malignant lesions in a number of situations,
but in others visual analysis has been reported to be equivalent
(Lowe et al, 1994). It is possible that visual analysis may often be
sufficient with an experienced interpreter. A number of studies
have shown that various forms of kinetic analysis have better
specificity (Dimitrakopoulou-Strauss et al, 2002) with improved
performance in lesions with borderline SUVs but at the expense of
greater scan acquisition and analysis complexity. There is less
evidence on the use of PET to determine grade of malignancy, with
few dynamic studies reported. However, there is some evidence
that
18FDG PET correlates with tumour grade and infers prognosis
in some tumour types, examples having been reported in bone,
breast and brain tumours, among others (Dimitrakopoulou-
Strauss et al, 2001; Borbely et al, 2006; Shimoda et al, 2007).
Assessment of response to treatment and treatment
modification
Several studies have demonstrated the ability to predict clinical or
pathological response at an early time point by measuring changes
in
18FDG tumour activity and to infer a better prognosis in
responders. The results of such studies imply that early changes in
tumour metabolism predict subsequent response and correlate
with outcome. The optimum time point for assessment is likely to
be variable, depending on individual tumours and their speed of
response to different treatments with variation in studies reflecting
different research questions. Wahl et al (1993) showed a reduction
in SUV and net
18FDG influx as early as 8 days after starting
chemohormonotherapy for primary breast cancer, which predated
changes in size and predicted ultimate pathological response.
Similarly, Weber et al (2001) have shown that a greater than 35%
reduction in SUV in gastro-oesophageal cancers after one cycle of
chemotherapy predicts pathological response and increased time
to progression and overall survival. Interim response assessment is
18FDG PET scanning in oncology
F Castell and GJR Cook
1599
British Journal of Cancer (2008) 98(10), 1597–1601 & 2008 Cancer Research UKalso being used after one or two cycles of chemotherapy to inform
subsequent management, completing therapy in responding
patients but intensifying or changing treatment in nonresponders.
This approach has been most extensively investigated in lympho-
ma (Israel et al, 2004).
There is general agreement that at least semiquantitative
techniques are superior to qualitative assessment alone in
monitoring treatment response (Young et al, 1999; Hoekstra
et al, 2000; Weber, 2005; Shankar et al, 2006) and are probably
sufficient for most routine clinical work. These methods may be
limited where maximal tumour response has not been achieved or
when there is an accompanying inflammatory response associated
with
18FDG activity. The careful timing of scans after injection is
also crucial to ensure maximal precision between scans.
A number of parameters may be affected by the metabolic
changes that occur as a result of therapy, such as plasma clearance
of
18FDG secondary to reduced renal function. This can affect the
assumptions made in interpretations of data, including that
the contribution of nonphosphorylated
18FDG to the total signal
can be ignored. This can result in the poorer performance of
qualitative and semiquantitative analysis. Weber (2005) suggested
that although changes in SUV are generally well correlated with
changes in net influx rate (Ki), this may not apply in tumours with
relatively low metabolic activity. In this situation, the contribution
of nonphosphorylated
18FDG to the total
18FDG signal cannot be
neglected, and therapy-induced changes in Ki may correlate less
well with changes in SUV. Because of these and other described
limitations of semiquantitative techniques, there will remain a role
for more complex and invasive dynamic scan acquisitions and
kinetic analysis to allow for better discrimination of responders
from nonresponders (Hoekstra et al, 2002), particularly in the
phase 1 trial setting or when novel tracers measuring different
pharmacodynamic end points are being used where less knowledge
exists on the kinetics of uptake. Compartmental modelling of
dynamic data is often the preferred form of analysis for
pharmacokinetic measurements of novel drugs as it allows a
detailed measure of the individual kinetic processes involved
(Willemsen and Van den Hoff, 2002).
CONCLUSION
Positron emission tomography has become an important part
of the management of cancer. Qualitative and semiquantitative
interpretation of static scans is probably sufficient for routine
clinical staging purposes. In lesions of uncertain significance,
semiquantitative techniques (e.g., SUV) may help guide inter-
pretation, although due to variability in
18FDG avidity between
different tumour types, may be limited in discrimination between
benign and malignant tissue in an individual case. For the
assessment of response to therapy, further studies are required.
Although semiquantitative measures usually suffice in the clinic, it
may be that the use of dynamic scanning with kinetic analysis is
more appropriate for drug development trials and may provide a
more accurate assessment of changes in tumour metabolism. This
may be worth the additional time and effort to perform as patient
treatment becomes more tailored to the individual, based on their
response to treatment received so far. However, although kinetic
approaches offer improved accuracy and discrimination, they are
practically more complex and validation of semiquantitative static
or simplified dynamic techniques would be particularly attractive
in this role.
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